Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $111,017.40 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 4,303 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the sale, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Peter Radovich also recently made the following trade(s):

• On Monday, January 8th, Peter Radovich sold 1,408 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $28.03, for a total transaction of $39,466.24.

Mirum Pharmaceuticals Stock Up 0.8 %

Shares of MIRM opened at $25.12 on Thursday. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.45 and a quick ratio of 4.19. The firm has a 50 day simple moving average of $27.49 and a 200-day simple moving average of $29.23. Mirum Pharmaceuticals, Inc. has a 1-year low of $21.83 and a 1-year high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. The business had revenue of $69.55 million for the quarter, compared to analysts’ expectations of $66.73 million. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on MIRM shares. Raymond James reduced their price objective on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating for the company in a research report on Tuesday, December 19th. JMP Securities raised their price objective on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, March 14th. SVB Leerink reduced their price objective on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Monday, March 18th. HC Wainwright lifted their price target on shares of Mirum Pharmaceuticals from $45.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $35.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $52.11.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Silverarc Capital Management LLC grew its stake in Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Silverarc Capital Management LLC now owns 106,375 shares of the company’s stock worth $2,752,000 after acquiring an additional 436 shares during the period. Metropolitan Life Insurance Co NY grew its stake in Mirum Pharmaceuticals by 49.7% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,464 shares of the company’s stock worth $38,000 after acquiring an additional 486 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Mirum Pharmaceuticals by 98.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after acquiring an additional 488 shares during the period. Los Angeles Capital Management LLC grew its stake in Mirum Pharmaceuticals by 1.2% in the 3rd quarter. Los Angeles Capital Management LLC now owns 42,444 shares of the company’s stock worth $1,341,000 after acquiring an additional 494 shares during the period. Finally, Royal Bank of Canada grew its stake in Mirum Pharmaceuticals by 40.1% in the 2nd quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock worth $48,000 after acquiring an additional 530 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.